Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07218380 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Study acronym: FORAGER-2
StatusRecruiting
PhasePhase 3
Started2025-12-12
View on ClinicalTrials.gov ↗
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.

Amendment history 2 changes detected by DataLookout

2026-08-18
Trial sites expanded: 286 → 289 locations
2026-07-08
Trial sites expanded: 284 → 287 locations
Trial Details
NCT Number NCT07218380
Lead Sponsor Eli Lilly and Company
Conditions Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Enrollment 450 participants
Start Date 2025-12-12
Primary Completion 2029-10 (estimated)
Study Completion 2033-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-21